Country directory
United States · US
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) NIH · Up to $1B · Nov 19, 2026
- ERDC Broad Agency Announcement DOD · Up to $1,000M · Jan 1, 2027
- Notice of Intent: Program to End Modern Slavery FY 2025 DOS · $2K–$200M · Jan 1, 2099
- Notice of Intent: Program to End Modern Slavery FY 2023 DOS · $2K–$200M · Jan 1, 2099